Woodline Partners LP Kronos Bio, Inc. Transaction History

Woodline Partners LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.82 - $1.07 $2,173 - $2,836	-2,651 Reduced 0.86%	306,946 $251,000
Q3 2024 Nov 14, 2024	BUY	$0.92 - $1.5 $284,829 - $464,395	309,597 New	309,597 $309,000
Q1 2023 May 15, 2023	BUY	$1.34 - $2.62 $126,954 - $248,224	94,742 Added 119.72%	173,877 $253,000
Q4 2022 Feb 14, 2023	SELL	$1.44 - $3.44 $12,670 - $30,268	-8,799 Reduced 10.01%	79,135 $128,000
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $842,320 - $1.4 Million	-251,439 Reduced 74.09%	87,934 $295,000
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $462,827 - $1.12 Million	148,342 Added 77.65%	339,373 $1.24 Million
Q1 2022 May 16, 2022	SELL	$6.26 - $14.42 $742,223 - $1.71 Million	-118,566 Reduced 38.3%	191,031 $1.38 Million
Q4 2021 Feb 14, 2022	SELL	$11.35 - $21.18 $2.17 Million - $4.05 Million	-191,031 Reduced 38.16%	309,597 $4.21 Million
Q2 2021 Aug 16, 2021	BUY	$20.08 - $29.02 $6.28 Million - $9.07 Million	312,543 Added 166.17%	500,628 $12 Million
Q1 2021 May 17, 2021	SELL	$27.0 - $32.48 $901,854 - $1.08 Million	-33,402 Reduced 15.08%	188,085 $5.51 Million
Q4 2020 Feb 16, 2021	BUY	$26.68 - $38.23 $5.91 Million - $8.47 Million	221,487 New	221,487 $6.62 Million

965K

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $50M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.